Vitamin D is a fat-soluble vitamin that regulates bone modeling and calcium metabolism. Although we absorb moderate amounts of the vitamin from foods such as milk and fatty fish, the majority of vitamin D is produced in the body when 7-dehydrocholesterol in the skin is exposed to ultraviolet (UV) B radiation to produce vitamin D3 (cholecalciferol).
. 5, 7, 8, 9 It is likely that the antiproliferative effects of 1,25(OH)2D3 are mediated in part by stalling the cell cycle at the G1/S checkpoint by increasing inhibitors and reducing activators of the cyclin-dependent kinase (CDK) complexes. This prevents DNA synthesis and cell growth.
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In addition, the enzyme 1-α-25-dihydroxyvitamin D3 24-hydroxylase (CYP24) is the primary enzyme responsible for the catabolic inactivation of 1,25(OH)2D3 and is considered a candidate oncogene. 12, 13 In this paper, we review the recent basic science and clinical research concerning vitamin D and the four most common malignancies: lung, breast, colorectal, and prostate cancer.
Lung Cancer
Lung cancer is the leading cause of mortality from cancer worldwide with only a 10 % survival rate at 5 years. 14 There are two main pathologic types of primary lung cancer, small cell (15 % of cases) and non-small cell (NSCLC) (about 85 % of all lung cancer cases). NSCLC has three subtypes:
squamous-cell carcinoma, adenocarcinoma, and large-cell lung cancer.
Despite advances in early detection and standard treatment, NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Smallcell lung cancer is aggressive and presents with metastatic disease in 60 % of cases. It is highly responsive to chemotherapy and radiotherapy but almost always relapses and is almost universally fatal.
There have been multiple in vitro studies that have established 1,25(OH)2D3 as an inhibitor of lung cancer growth. 15, 16 Vitamin D demonstrates antiproliferative effects in several epithelial-derived stem cell lines such as the NCI-H82 and NCI-H209 small cell lung carcinoma 17 and the EBC-1 and H520 nonsmall cell carcinoma cell lines. 18 The exact mechanism of this regulation is still being elucidated. In colorectal carcinoma cultures, vitamin D has also been found to modify both phase I and II enzymes involved in reduction, oxidation, hydrolysis, and conjugation-all important for the removal of compounds that may contribute to the formation of cancer. 69 Furthermore, vitamin D has been showed to regulate the expression of members of the multidrug resistance-associated protein family that are responsible for the efflux of potentially toxic conjugates from the intracellular milieu. 70, 71 There is a substantial amount of epidemiologic literature that examines the relationship between vitamin D and the risk for colorectal cancer.
Garland and Garland published a paper in 1980 that proposed an inverse relation between latitude and colorectal cancer mortality. 72 In 1989, an inverse association between vitamin D and colorectal cancer status in the US was established. 73 A recent meta-analysis of 35 independent studies confirmed a consistent inverse relationship between serum vitamin D levels and the risk for developing colorectal cancer. 74 Additionally, a systematic review of 18 prospective studies that assessed the association of vitamin D intake or serum levels of 25(OH)D2 and the risk for colorectal cancer in approximately 1,000,000 individuals was performed. They found an inverse association between both serum 25(OH)D2 and vitamin D intake and the risk for developing colorectal cancer. 75 86 This finding was demonstrated after transfection of 1-α-hydroxylase cDNA into a prostate cancer cell line increased 1-α-hydroxylase activity significantly. 87 Given this in vitro data, other studies have been performed to examine the correlation between UV light exposure and incidence of prostate cancer or prostate cancer mortality. Of the nine studies that have been performed since 2011, seven of the studies show reduced UV light exposure increases prostate cancer risk. [88] [89] [90] [91] [92] [93] [94] Additionally, the two studies that did not show an increase in the risk for prostate cancer in the setting of reduced UV light did show a difference in mortality for the season of diagnosis. 95, 96 Given the mixed UV exposure data, we have found 15 case-cohort or case-control studies examining serum vitamin D and its relationship to prostate cancer risk or mortality. Ten of these studies did not find an association between low vitamin D levels (either 1,25(OH)2D3 or 25(OH) D2) and prostate cancer risk or mortality. [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] Five studies show an increase in prostate cancer risk or mortality with low vitamin D; [107] [108] [109] [110] [111] one of them shows a decreased risk for lethal cancer 107 and two of them demonstrate an increased risk for aggressive cancer. 110, 111 Of note, two studies show an increased risk with higher levels of 25(OH)D2 108,110 and one study shows a possible increased risk for aggressive cancer with higher levels of 25(OH)D2.
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While the epidemiologic data is promising for vitamin D as a potential therapy in prostate cancer, the use of 1,25(OH)2D3 comes at a cost of hypercalcemia, which comes with its own set of toxicities. Unfortunately, hypercalcemia is shown in some studies to be associated with either an increase in the risk for prostate cancer/and or an increase in the risk for high-grade prostate cancer. [112] [113] [114] [115] [116] [117] [118] In an effort to increase efficacy and decrease toxicity, the use of vitamin D and its analogues have been studied in combination with other agents.
There are many phase II clinical trials that show calcitriol decreases the levels of prostate-specific antigen. [119] [120] [121] [122] [123] [124] One of these studies did show an improved survival with a formulation of calcitriol in combination with cytotoxic docetaxel, although the phase II study was stopped early in the setting of excess deaths. 
